Usage and dosage of Riflimab: Instructions on injection frequency and treatment duration

Retifanlimab - Zynyz is a new immune checkpoint inhibitor that belongs to the anti-PD-1 monoclonal antibody class and is widely used in the treatment of a variety of advanced solid tumors, especially in patients with previously treated Merkel cell carcinoma. The drug specifically binds to the programmed cell death protein 1 (PD-1) and blocks its interaction with the ligands PD-L1 and PD-L2, thereby releasing the suppression of the immune system by the tumor microenvironment, enhancing the anti-tumor immune response mediated by T cells, and exerting a long-lasting anti-cancer effect.

In clinical practice, the recommended dose of Riflimab is500 mg, administered by intravenous infusion, with each infusion time controlled within 30 minutes to ensure drug safety and patient tolerance. This dosing regimen is based on pharmacokinetic and pharmacodynamic study results and is designed to maintain stable plasma drug concentrations and continuously and effectively inhibit the PD-1 pathway. The dosing frequency is set to once every 4 weeks (a 28-day cycle). This interval not only ensures the continuity of efficacy, but also gives patients appropriate recovery time and reduces the risk of immune-related adverse events. The length of treatment depends on the patient's specific condition. It is usually recommended to continue taking the medication until the disease progresses, intolerable side effects occur, or the patient chooses to stop treatment.

During the course of treatment, patients need to undergo regular imaging evaluation and clinical monitoring to evaluate treatment response and adjust the plan. The medical team should pay close attention to the patient's physical status, laboratory indicators, and potential immune-related toxicities, and intervene in a timely manner. Special groups such as those with hepatic and renal insufficiency, elderly patients, and patients with a history of autoimmunity should use it with caution, and adjust the dosage and monitoring frequency under the guidance of a professional doctor.

Overall, the usage and dosage regimen of Riflimab is scientific and reasonable, reflecting the trend of individualization and precision of modern immunotherapy, and is an important progress in the current field of cancer immunotherapy.

Reference materials:https://www.drugs.com/mtm/retifanlimab.html